SI1442030T1 - Tiofensulfonamidi in tiazolsulfonamidi kot antineoplasticna sredstva - Google Patents

Tiofensulfonamidi in tiazolsulfonamidi kot antineoplasticna sredstva

Info

Publication number
SI1442030T1
SI1442030T1 SI200230399T SI200230399T SI1442030T1 SI 1442030 T1 SI1442030 T1 SI 1442030T1 SI 200230399 T SI200230399 T SI 200230399T SI 200230399 T SI200230399 T SI 200230399T SI 1442030 T1 SI1442030 T1 SI 1442030T1
Authority
SI
Slovenia
Prior art keywords
thiazolesulfonamides
thiopene
amd
antineoplastic agents
antineoplastic
Prior art date
Application number
SI200230399T
Other languages
English (en)
Slovenian (sl)
Inventor
Dios Alfonso Lilly S A De
Cora Sue Grossman
Philip Arthur Hipskind
Ho-Shen Lin
Karen Lynn Lobb
De Uralde Garmendia Beat Lopez
Jose Eduardo Lopez
Mary Margaret Mader
Michael Enrico Richett
Chaun Shih
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SI1442030T1 publication Critical patent/SI1442030T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200230399T 2001-10-25 2002-10-15 Tiofensulfonamidi in tiazolsulfonamidi kot antineoplasticna sredstva SI1442030T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35201201P 2001-10-25 2001-10-25
PCT/US2002/031568 WO2003035629A1 (en) 2001-10-25 2002-10-15 Thiopene- amd thiazolesulfonamides as antineoplastic agents
EP02802117A EP1442030B1 (en) 2001-10-25 2002-10-15 Thiopene- amd thiazolesulfonamides as antineoplastic agents

Publications (1)

Publication Number Publication Date
SI1442030T1 true SI1442030T1 (sl) 2006-12-31

Family

ID=23383421

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200230399T SI1442030T1 (sl) 2001-10-25 2002-10-15 Tiofensulfonamidi in tiazolsulfonamidi kot antineoplasticna sredstva

Country Status (33)

Country Link
US (2) US7084170B2 (https=)
EP (1) EP1442030B1 (https=)
JP (1) JP4464681B2 (https=)
KR (1) KR100913471B1 (https=)
CN (1) CN1298709C (https=)
AR (1) AR037248A1 (https=)
AT (1) ATE338033T1 (https=)
AU (1) AU2002334817B2 (https=)
BR (1) BR0212386A (https=)
CA (1) CA2463300C (https=)
CY (1) CY1106247T1 (https=)
DE (1) DE60214413T2 (https=)
DK (1) DK1442030T3 (https=)
EA (1) EA006081B1 (https=)
EC (1) ECSP045078A (https=)
EG (1) EG26021A (https=)
ES (1) ES2269816T3 (https=)
HR (1) HRP20040371B1 (https=)
HU (1) HUP0401638A3 (https=)
IL (2) IL160851A0 (https=)
MX (1) MXPA04003886A (https=)
MY (1) MY130718A (https=)
NO (1) NO20041316L (https=)
NZ (1) NZ531136A (https=)
PE (1) PE20030574A1 (https=)
PL (1) PL208083B1 (https=)
PT (1) PT1442030E (https=)
SI (1) SI1442030T1 (https=)
SV (1) SV2004001367A (https=)
TW (1) TWI281916B (https=)
UA (1) UA75716C2 (https=)
WO (1) WO2003035629A1 (https=)
ZA (1) ZA200403089B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101624391A (zh) * 2001-06-11 2010-01-13 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
AU2003249683A1 (en) * 2002-06-06 2003-12-22 Smithkline Beecham Corporation Nf-:b inhibitors
US7402608B2 (en) * 2002-12-10 2008-07-22 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
JP5134247B2 (ja) * 2004-09-13 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有化合物の血管新生阻害物質との併用
EP2364699A1 (en) * 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
WO2006090927A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の摂食亢進作用
PL1859793T3 (pl) * 2005-02-28 2011-09-30 Eisai R&D Man Co Ltd Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej
JPWO2006090928A1 (ja) * 2005-02-28 2008-07-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の血管新生阻害物質との新規併用
BRPI0610283A2 (pt) * 2005-05-13 2010-10-19 Virochem Pharma Inc composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
US7208506B2 (en) * 2005-07-07 2007-04-24 Hoffmann-La Roche Inc. Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
US7625896B2 (en) * 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
US20100291592A1 (en) 2006-04-20 2010-11-18 Taro Semba Novel marker for sensitivity against sulfonamide compound
US7939532B2 (en) * 2006-10-26 2011-05-10 Hoffmann-La Roche Inc. Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
CA2670260A1 (en) 2006-11-15 2008-05-22 Virochem Pharma Inc. Thiophene analogues for the treatment or prevention of flavivirus infections
US7879884B2 (en) 2007-05-16 2011-02-01 Hoffmann-La Roche Inc. Aryl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
CN101899008B (zh) * 2010-05-20 2012-10-17 中国人民解放军第二军医大学 N-取代嘧啶磺酰基-取代苯甲酰胺类化合物及其制备药物的用途
CN103450149B (zh) * 2012-06-01 2015-10-14 中国科学院上海有机化学研究所 苯基噻吩磺酰胺类化合物及其制备方法和用途
JP6364967B2 (ja) * 2014-05-30 2018-08-01 東ソー株式会社 ジチエノベンゾジチオフェンの製造方法
CN106588868A (zh) * 2016-11-16 2017-04-26 武汉理工大学 一种2‑溴‑3‑噻吩甲酸中间体的合成方法
CN108558822B (zh) * 2018-06-01 2020-12-18 盐城锦明药业有限公司 N-((5-溴噻吩-2-基)磺酰基)-2,4-二氯苯甲酰胺的合成方法
CN110835345A (zh) * 2018-08-17 2020-02-25 中国科学院上海药物研究所 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
CN109265437A (zh) * 2018-10-19 2019-01-25 凯莱英医药集团（天津）股份有限公司 一种3-羟基噻吩-2-羧酸酯类化合物的制备方法
EP4724106A1 (en) * 2023-06-07 2026-04-15 Kræftens bekæmpelse Protacs and hyt-pd molecules for targeted protein degradation of dcaf15 and their use in the treatment of amyloidosis
WO2025031361A1 (zh) * 2023-08-09 2025-02-13 上海科技大学 磺酰胺类化合物作为制备治疗癌症药物的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA813332B (en) * 1980-06-21 1982-05-26 Pfizer Larvicides and isecticides
IL98784A0 (en) 1990-07-17 1992-07-15 Lilly Co Eli Heterocyclyl sulfonamide derivatives,process for their preparation and pharmaceutical compositions containing them
US5177074A (en) * 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5169860A (en) * 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
WO1998001440A2 (en) * 1996-07-05 1998-01-15 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof
WO1998014440A1 (en) 1996-10-04 1998-04-09 Eli Lilly And Company Antitumor compositions and methods of treatment
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、

Also Published As

Publication number Publication date
EG26021A (en) 2012-12-10
KR100913471B1 (ko) 2009-08-25
KR20040062583A (ko) 2004-07-07
DE60214413T2 (de) 2007-03-08
MY130718A (en) 2007-07-31
CY1106247T1 (el) 2011-06-08
CA2463300C (en) 2011-07-19
HUP0401638A3 (en) 2012-09-28
EP1442030B1 (en) 2006-08-30
IL160851A0 (en) 2004-08-31
JP4464681B2 (ja) 2010-05-19
TWI281916B (en) 2007-06-01
ES2269816T3 (es) 2007-04-01
US20060223871A1 (en) 2006-10-05
UA75716C2 (en) 2006-05-15
IL160851A (en) 2009-11-18
US7084170B2 (en) 2006-08-01
NZ531136A (en) 2006-08-31
EP1442030A1 (en) 2004-08-04
ZA200403089B (en) 2005-04-22
CN1575286A (zh) 2005-02-02
EA200400582A1 (ru) 2004-08-26
CN1298709C (zh) 2007-02-07
US20040198784A1 (en) 2004-10-07
PL368234A1 (en) 2005-03-21
HRP20040371A2 (en) 2004-08-31
HRP20040371B1 (en) 2012-07-31
DE60214413D1 (de) 2006-10-12
WO2003035629A1 (en) 2003-05-01
EA006081B1 (ru) 2005-08-25
NO20041316L (no) 2004-03-30
BR0212386A (pt) 2004-07-27
SV2004001367A (es) 2004-02-24
PE20030574A1 (es) 2003-07-03
MXPA04003886A (es) 2004-07-08
JP2005511547A (ja) 2005-04-28
HK1068337A1 (en) 2005-04-29
ATE338033T1 (de) 2006-09-15
DK1442030T3 (da) 2006-12-27
AU2002334817B2 (en) 2008-02-21
PL208083B1 (pl) 2011-03-31
ECSP045078A (es) 2004-06-28
PT1442030E (pt) 2006-12-29
CA2463300A1 (en) 2003-05-01
US7250430B2 (en) 2007-07-31
HUP0401638A2 (hu) 2004-11-29
AR037248A1 (es) 2004-11-03

Similar Documents

Publication Publication Date Title
IL160851A0 (en) Thiopene-and thiazolesulfonamides as antineoplastic agents
IL159859A0 (en) Antineoplastic combinations
IL158800A0 (en) Antineoplastic combinations
ZA200603888B (en) Antineoplastic combinations
AU2002360430A8 (en) 14-methyl-epothilones
IL160539A0 (en) Anti-influenzal agents
GB0202267D0 (en) Autotensioner
GB0125492D0 (en) Formulation
AU2002313943A8 (en) Electromobile
GB2375048B (en) Formulation
GB2396812B (en) Formulation
GB0116619D0 (en) Formulation
AU2001100134A4 (en) Enviro-trap
GB0112497D0 (en) Formulation
CA92665S (en) Bedboard
CA93125S (en) Tilt-latch
CA93126S (en) Titlt-latch
CA93959S (en) Tilt-latch
CA93075S (en) Travelbag
CA92978S (en) Photo-changer
CA91502S (en) Bedboard
AU2479P (en) Crackerjack xTriticosecale
AU2288P (en) Prime322 xTriticosecale
GB0127639D0 (en) Project ccfc
GB0110657D0 (en) Choice